Journal article
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial
Gynecologic oncology, Vol.127(3), pp.440-450
12/2012
DOI: 10.1016/j.ygyno.2012.08.033
PMID: 22940493
Abstract
We evaluated baseline data from the PApilloma TRIal against Cancer In young Adults (PATRICIA; NCT00122681) on the association between behavioral risk factors and HPV infection and cervical abnormalities.
Women completed behavioral questionnaires at baseline. Prevalence of HPV infection and cervical abnormalities (detected by cytological or histological procedures) and association with behavioral risk factors were analyzed by univariate and stepwise multivariable logistic regressions.
16782 women completed questionnaires. Among 16748 women with data for HPV infection, 4059 (24.2%) were infected with any HPV type. Among 16757 women with data for cytological abnormalities, 1626 (9.7%) had a cytological abnormality, of whom 1170 (72.0%) were infected with at least one oncogenic HPV type including HPV-16 (22.7%) and HPV-18 (9.3%). Multivariable analysis (adjusted for age and region, N=14404) showed a significant association between infection with any HPV type and not living with a partner, smoking, age <15years at first sexual intercourse, higher number of sexual partners during the past 12months, longer duration of hormonal contraception and history of sexually transmitted infection (STI). For cervical abnormalities, only history of STI (excluding Chlamydia trachomatis) remained significant in the multivariable analysis after adjusting for HPV infection.
Women reporting 3+ sexual partners in the past 12months had the highest risk of HPV infection at baseline. HPV infection was the main risk factor for cervical abnormalities, and history of STIs excluding Chlamydia trachomatis increased risk to a lesser extent. Although behavioral factors can influence risk, all sexually active women are susceptible to HPV infection.
► Women with ≥3 sexual partners in the past 12m had the highest risk of HPV infection. ► HPV infection was the main risk factor for cervical abnormalities. ► History of STIs excluding C trachomatis increased this risk to a lesser extent.
Details
- Title: Subtitle
- Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial
- Creators
- Edith Roset Bahmanyar - GlaxoSmithKline Vaccines, Wavre, BelgiumJorma Paavonen - Department of Obstetrics and Gynaecology, University of Helsinki, FinlandPaulo Naud - University Federal of Rio Grande do Sul, Hospital de Clínica de Porto Alegre, Porto Alegre, BrazilJorge Salmerón - Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social, Morelos, MexicoSong-Nan Chow - Department of Obstetrics and Gynecology, College of Medicine and the Hospital, National Taiwan University, Taipei, TaiwanDan Apter - Family Federation of Finland, Sexual Health Clinic, Helsinki, FinlandXavier Castellsagué - Institut Català d'Oncologia, IDIBELL, CIBER-ESP, RTICC, L'Hospitalet de Llobregat, Catalonia, SpainJulio C Teixeira - University of Campinas, Campinas, BrazilS. Rachel Skinner - Vaccine Trials Group, Telethon Institute for Child Health Research, Perth, WA and Sydney University Discipline of Paediatrics and Child Health, Children's Hospital Westmead, Sydney, NSW, AustraliaUnnop Jaisamrarn - Chulalongkorn University, Department of Obstetrics and Gynaecology, Faculty of Medicine, Bangkok, ThailandGenara A Limson - University of the Philippines, College of Medicine, Philippine General Hospital, Makati Medical Center, Makati City, PhilippinesSuzanne M Garland - Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville/Department of Microbiology, The Royal Children's Hospital, Parkville/Murdoch Children's Research Institute, Parkville/Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria, AustraliaAnne Szarewski - Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UKBarbara Romanowski - University of Alberta, Edmonton, Alberta, CanadaFred Aoki - University of Manitoba, Winnipeg, MB, CanadaTino F Schwarz - Central Laboratory and Vaccination Centre, Stiftung Juliusspital, Academic Teaching Hospital of the University of Wuerzburg, Wuerzburg, GermanyWilly A.J Poppe - Department of Gynaecology, University Hospital KU Leuven Gasthuisberg, Leuven, BelgiumNewton S De Carvalho - Department of Gynecology and Obstetrics, Federal University of Paraná, Infectious Diseases in Gynaecology and Obstetrics Sector, Curitiba, Parana, BrazilDiane M Harper - Department of Obstetrics and Gynaecology, Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, USAF. Xavier Bosch - Institut Català d'Oncologia, IDIBELL, CIBER-ESP, RTICC, L'Hospitalet de Llobregat, Catalonia, SpainAlice Raillard - 4Clinics, Paris, FranceDominique Descamps - GlaxoSmithKline Vaccines, Wavre, BelgiumFrank Struyf - GlaxoSmithKline Vaccines, Wavre, BelgiumMatti Lehtinen - University of Tampere, School of Public Health, Tampere, FinlandGary Dubin - GlaxoSmithKline Vaccines, King of Prussia, PA, USAHPV PATRICIA Study Group
- Contributors
- T J Stapleton (Contributor) - University of Iowa, Internal Medicine
- Resource Type
- Journal article
- Publication Details
- Gynecologic oncology, Vol.127(3), pp.440-450
- Publisher
- Elsevier Inc
- DOI
- 10.1016/j.ygyno.2012.08.033
- PMID
- 22940493
- ISSN
- 0090-8258
- eISSN
- 1095-6859
- Grant note
- DOI: 10.13039/100004330, name: GlaxoSmithKline; DOI: 10.13039/100004330, name: GlaxoSmithKline
- Language
- English
- Date published
- 12/2012
- Academic Unit
- Microbiology and Immunology; Infectious Diseases; Internal Medicine
- Record Identifier
- 9984094509802771
Metrics
18 Record Views